Current Report Filing (8-k)
September 12 2017 - 4:55PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C.
20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
September 12, 2017 (September 6, 2017)
Date
of
Report
(Date
of
earliest
event
reported)
HELIUS MEDICAL TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
WYOMING
|
000-55364
|
36-4787690
|
(State or other jurisdiction of
|
(Commission
|
(I.R.S. Employer
|
incorporation or organization)
|
File Number)
|
Identification No.)
|
(Exact name
of
registrant as
specified
in
charter)
642 Newtown Yardley Road Suite 100
Newtown, Pennsylvania, 18940
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (215) 944-6100
Check
the
appropriate
box
below
if
the
Form
8-K
filing
is
intended
to
simultaneously
satisfy
the
filing
obligation
of
the
registrant
under
any
of
the
following
provisions:
|
☐
|
Written
communications
pursuant
to
Rule
425
under
the
Securities
Act
(17
CFR
230.425)
|
|
☐
|
Soliciting
material
pursuant
to
Rule
14a12
under
the
Exchange
Act
(17
CFR
240.14a12)
|
|
☐
|
Precommencement
communications
pursuant
to
Rule
14d2(b)
under
the
Exchange
Act
(17
CFR
240.14d2(b))
|
|
☐
|
Precommencement
communications
pursuant
to
Rule
13e4(c)
under
the
Exchange
Act
(17
CFR
240.13e4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b‑2 of the Securities Exchange Act of 1934 (§240.12b‑2 of this chapter).
Emerging growth company
☑
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act
☑
1
Item 1.01
|
Entry into a Material Definitive Agreement
|
Helius Medical Technologies, Inc. (the “Company”) is designing PoNS™ Therapy with the cooperation of the U.S. Army pursuant to an agreement known as a cooperative research and development agreement. On September 6, 2017, the Company’s wholly-owned subsidiary NeuroHabilitation Corporation, as cooperator, entered into Notice of Modification No. 4 (“Modification No. 4”) of the Amended Cooperative Research and Development Agreement (“CRADA”), with Advanced NeuroRehabilitation, LLC, Yuri Danilov, Mitchell Tyler, Kurt Kaczmarek, the U.S. Army Medical Materiel Agency and the U.S. Army Medical Materiel Development Activity. Modification No. 4 extends the expiration date of the CRADA to December 31, 2018 and extends the deadline for commercialization of the PoNS™ Therapy through December 31, 2021.
The preceding summary of the CRADA and the amendments thereto is qualified in its entirety by reference to Modification No. 4 which is attached hereto as Exhibit 2.1, the CRADA (filed as Exhibit 10.2 to the Company’s Form S-1 filed July 14, 2014), Modification No. 1 to the CRADA (filed as Exhibit 10.5 to the Company’s Form S-1 filed July 14, 2014), Modification No. 2 to the CRADA (filed as Exhibit 10.12 to the Form 10-12G filed on February 6, 2015) and Modification No. 3 to the CRADA (filed as Exhibit 2.1 to the Form 8-K filed on December 31, 2015).
Item 9.01.
Financial Statements and Exhibits.
(d) Exhibits
2
EXHIBIT INDEX
3
SIGNATURE
Pursuant
to
the
requirements
of
the
Securities
Exchange
Act
of
1934,
the
registrant
has
duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized
.
|
HELIUS MEDICAL TECHNOLOGIES, INC.
|
|
|
|
Dated: September 12, 2017
|
By:
|
/s/ Joyce LaViscount
|
|
|
Joyce LaViscount, Chief Financial Officer
|
4
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Sep 2023 to Sep 2024